JPWO2017184774A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2017184774A5 JPWO2017184774A5 JP2018554700A JP2018554700A JPWO2017184774A5 JP WO2017184774 A5 JPWO2017184774 A5 JP WO2017184774A5 JP 2018554700 A JP2018554700 A JP 2018554700A JP 2018554700 A JP2018554700 A JP 2018554700A JP WO2017184774 A5 JPWO2017184774 A5 JP WO2017184774A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- following compound
- selective inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124639 Selective inhibitor Drugs 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 9
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims description 6
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 102000011427 Histone Deacetylase 6 Human genes 0.000 claims 18
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 18
- 229940124291 BTK inhibitor Drugs 0.000 claims 10
- 229940126062 Compound A Drugs 0.000 claims 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 6
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 6
- 229960001507 ibrutinib Drugs 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000000527 lymphocytic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104680A JP2022121599A (ja) | 2016-04-19 | 2022-06-29 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| JP2024095101A JP2024111024A (ja) | 2016-04-19 | 2024-06-12 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324733P | 2016-04-19 | 2016-04-19 | |
| US62/324,733 | 2016-04-19 | ||
| PCT/US2017/028435 WO2017184774A1 (en) | 2016-04-19 | 2017-04-19 | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104680A Division JP2022121599A (ja) | 2016-04-19 | 2022-06-29 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515909A JP2019515909A (ja) | 2019-06-13 |
| JPWO2017184774A5 true JPWO2017184774A5 (https=) | 2022-07-19 |
| JP2019515909A5 JP2019515909A5 (https=) | 2022-07-19 |
Family
ID=60117010
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554700A Pending JP2019515909A (ja) | 2016-04-19 | 2017-04-19 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| JP2022104680A Pending JP2022121599A (ja) | 2016-04-19 | 2022-06-29 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| JP2024095101A Pending JP2024111024A (ja) | 2016-04-19 | 2024-06-12 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104680A Pending JP2022121599A (ja) | 2016-04-19 | 2022-06-29 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| JP2024095101A Pending JP2024111024A (ja) | 2016-04-19 | 2024-06-12 | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11813261B2 (https=) |
| EP (1) | EP3445364A4 (https=) |
| JP (3) | JP2019515909A (https=) |
| WO (1) | WO2017184774A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2929576T3 (es) * | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| EP3445364A4 (en) | 2016-04-19 | 2019-11-27 | Acetylon Pharmaceuticals, Inc. | HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| TW201803594A (zh) * | 2016-06-09 | 2018-02-01 | 達納-法伯癌症協會 | Hdac抑制劑與bet抑制劑之使用方法及醫藥組合 |
| US11497746B2 (en) | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
| US11433069B2 (en) | 2017-12-01 | 2022-09-06 | University of Modena and Reggio Emilia | Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and JAK1/2 inhibitors |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| AU2022270657A1 (en) | 2021-05-04 | 2023-11-16 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| CA2463821A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| OA12793A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| DK1651618T3 (da) | 2003-07-24 | 2007-05-14 | Basf Ag | 2-substituerede pyrimidiner |
| PT1673349E (pt) | 2003-09-22 | 2010-09-28 | S Bio Pte Ltd | Derivados benzimidazole: preparação e aplicações farmacêuticas |
| KR101153335B1 (ko) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| WO2005097747A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP1940805A4 (en) | 2005-08-26 | 2009-11-11 | Methylgene Inc | BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE |
| ES2384182T3 (es) | 2005-11-01 | 2012-07-02 | Sumitomo Chemical Company, Limited | Proceso para la producción de 6,6-dimetil-3-oxabiciclo[3,1,0]hexan-2-ona |
| KR20080091297A (ko) | 2006-02-07 | 2008-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | Ｎ-히드록시아크릴아미드 화합물 |
| AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| CA2654540C (en) | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| WO2008102348A1 (en) | 2007-02-21 | 2008-08-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
| KR101325374B1 (ko) | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| AU2010203512C1 (en) | 2009-01-08 | 2013-10-17 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| EP2638009A4 (en) | 2010-01-08 | 2014-06-11 | Harvard College | FLUORINATED HDAC HEMMER AND USES THEREOF |
| TWI600638B (zh) | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| BR112013011868A2 (pt) | 2010-11-16 | 2016-08-23 | Acetylon Pharmaceuticals Inc | compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| WO2013059738A2 (en) | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| EP3004141A4 (en) | 2013-06-03 | 2017-05-31 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| WO2015054474A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| EP3054954A4 (en) * | 2013-10-10 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| CA2926808A1 (en) | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
| SG11201700094TA (en) * | 2014-07-07 | 2017-02-27 | Acetylon Pharmaceuticals Inc | Treatment of leukemia with histone deacetylase inhibitors |
| EP3445364A4 (en) | 2016-04-19 | 2019-11-27 | Acetylon Pharmaceuticals, Inc. | HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
-
2017
- 2017-04-19 EP EP17786584.7A patent/EP3445364A4/en active Pending
- 2017-04-19 US US16/093,278 patent/US11813261B2/en active Active
- 2017-04-19 JP JP2018554700A patent/JP2019515909A/ja active Pending
- 2017-04-19 WO PCT/US2017/028435 patent/WO2017184774A1/en not_active Ceased
-
2022
- 2022-06-29 JP JP2022104680A patent/JP2022121599A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095101A patent/JP2024111024A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515909A5 (https=) | ||
| US20230346788A1 (en) | Methods for treating viral disorders | |
| US20240390375A1 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| CN116712552A (zh) | 用于治疗疱疹病毒诱导的病况的方法和组合物 | |
| JP2019517587A5 (https=) | ||
| KR20220110261A (ko) | 코로나바이러스의 치료 방법 | |
| JPWO2017184774A5 (https=) | ||
| JP2004521856A (ja) | Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物 | |
| JP2008535873A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| JP2020536048A5 (https=) | ||
| JP2005519936A5 (https=) | ||
| JP2009242360A (ja) | 経口用の慢性疼痛予防または治療剤 | |
| CN115381939A (zh) | 治疗霍奇金淋巴瘤的药物组合物及其用途 | |
| JP2006104186A (ja) | 感冒用医薬組成物 | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| JP2021511352A5 (https=) | ||
| JP2006096749A (ja) | 感冒用医薬組成物 | |
| JP2009532494A (ja) | 高血圧処置のためのレニン阻害剤 | |
| JP2021530568A5 (https=) | ||
| JP2021512140A5 (https=) | ||
| JP2023518430A (ja) | 感染症の治療におけるブシラミンの使用 | |
| CN114073698A (zh) | 一种止痛止痒药物组合物及其应用方法 |